PDCD1 and neoplasm: A combination of DU102 and anti-PD-1 has higher numbers of tumor-infiltrated CD3+ T cells, CD3+CD8+ T cells, and CD3+CCR5+ T cells in B16-F10 tumors than those in B16-F10 tumors treated by either DU102 or anti-PD-1 alone (Fig. 7d and e, Supplementary Fig. S7f), while there was no difference in tumor-infiltrated CD3+CD4+ T cells (Supplementary Fig. S7e).